A5101419034- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Liver physiology and pathology
- SARS-CoV-2 and COVID-19 Research
- RNA modifications and cancer
- Urological Disorders and Treatments
- HIV, Drug Use, Sexual Risk
- COVID-19 Clinical Research Studies
- Tissue Engineering and Regenerative Medicine
- Ferroptosis and cancer prognosis
- Organ Transplantation Techniques and Outcomes
- Cancer-related molecular mechanisms research
- Hepatocellular Carcinoma Treatment and Prognosis
- Immunodeficiency and Autoimmune Disorders
- Cancer, Hypoxia, and Metabolism
- Pediatric Urology and Nephrology Studies
Zhejiang University
2014-2022
First Affiliated Hospital Zhejiang University
2009-2022
State Key Laboratory of Diagnosis and Treatment of Infectious Diseases
2014-2021
Objective The SARS-CoV-2-infected disease (COVID-19) outbreak is a major threat to human beings. Previous studies mainly focused on Wuhan and typical symptoms. We analysed 74 confirmed COVID-19 cases with GI symptoms in the Zhejiang province determine epidemiological, clinical virological characteristics. Design hospital patients were admitted from 17 January 2020 8 February 2020. Epidemiological, demographic, clinical, laboratory, management outcome data of using multivariate analysis for...
Liver cancer is one of the most common malignant tumors, and which hepatocellular carcinoma (HCC). We aim to study characteristic changes numerous genes their roles in HCC through systematical analysis characteristics expression spectrum HCC. Firstly, we made systematic clustering samples according RNAseq data from TCGA (The Cancer Genome Atlas) newly classified Then different molecular subtypes were found out further analyzed combing with methylation SNP 6.0 chip. Finally, these subjected...
Aim: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are equally recommended as the first-line antiviral treatments for chronic hepatitis B (CHB) at present. We aimed to compare long-term efficacy safety between ETV TDF therapy in CHB patients who had not received nucleoside analog treatment. Method: In this single-center retrospective study, 414 (290 patients) or (124 our center from January 2017 May 2019 were included. To reduce imbalance of baseline variables, propensity score...
This study investigated the possible use of interleukin (IL)-23 and IL-17 serum levels as indicators for anti-hepatitis B virus (HBV) therapy.A total 127 patients with chronic hepatitis (CHB) who received pegylated interferon (PegIFN) therapy, 20 asymptomatic HBV carriers (AsCs) 32 healthy controls were recruited. The IL-23 detected by ELISA. predictive value baseline early on-treatment changes in therapeutic response evaluated receiver operating characteristic analysis. Multivariate...